Furthermore, in some circumstances, although the tagged-version of TRAIL show toxicity on primary hepatocytes and on hepatic explants from patients with impaired liver function, the same compounds were largely safe on hepatic explants obtained from healthy donors, supporting the potentiality of TRAIL targeting for HCC cancer therapy although great caution in the administration of TRAIL to patients with impaired liver function must be taken into account [11]. The gene discussed is TNFSF10; the disease is cancer.